Antengene XPOVIO sNDA Hong-Kong Approval Expands MM DLBCL Indications
Antengene Corporation Limited (HKG: 6996) announced that Hong Kong’s Department of Health approved two supplementary...
Duality DB-1324 ADC FDA IND Approval Advances GSK Partnership
Duality Biotherapeutics, Inc. (HKG: 9606) announced that its Investigational New Drug (IND) application for DB-1324,...
NHSA Guangzhou Drug-List Conference Releases 2025 Medical Insurance Formulary
The National Healthcare Security Administration (NHSA) announced it will host the 2025 Innovative Drugs High-Quality...
Simcere deuremidevir RSV Licensing Deal Targets China Breakthrough
Simcere Pharmaceutical Group Limited (HKG: 2096) and Vigonvita Life Sciences Co., Ltd. (HKG: 2630) entered...
Henlius Fovinaciclib CDK4-6 Breast-Cancer China Commercialization
Henlius Biotech (HKG: 2696) announced a collaboration with Avanc Pharmaceutical Co., Ltd. to advance the...
Hengrui Remimazolam ICU Sedation NMPA Application Accepted
Jiangsu Hengrui Pharmaceutical Co., Ltd (SHA: 600276, HKG: 1276) announced that China’s National Medical Products...
Novo Nordisk CagriSema Pediatric Obesity Trial to Enroll 460 Children
Novo Nordisk (NYSE: NVO) is planning to test its experimental obesity drug CagriSema in overweight...
Antengene ATG-022 CLDN18.2 ADC Gets China Nod for Keytruda Combo in Gastric Cancer
Antengene Corporation Limited (HKG: 6996) announced that China’s National Medical Products Administration (NMPA) has approved...
MSD MK-2214 Fast Track Alzheimer Data Positive
Merck Sharp & Dohme Inc. (MSD, NYSE: MRK) released first‑in‑human data for MK-2214 and MK-1167 in...
China Drug-Price Registration System Launches with First Batch of 10 Products
China’s Drug Price Registration System officially launched today with the first batch of 10 drug...
3SBio HK$3.1B Placement Funds R&D Pipeline for 705, 706, 008
3SBio Inc. (HKG: 1530) conditionally agreed to place 105,169,500 shares at HK$29.62 per share, raising...
Generate GB-0895 Asthma Phase III Trials to Enroll 1,600 Patients
Generate: Biomedicines today announced plans to initiate two global Phase III clinical trials (SOLAIRIA-1 and...
Henlius HLX14 Denosumab Biosimilar NDA Accepted by China CDE
Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that the National Medical Products Administration’s Center for...
New-Radiomedicine Series-D Raises 800M Yuan for Radiopharmaceuticals
Chengdu New Radiomedicine Technology Co., Ltd. announced completion of its Series D financing round, raising...
Kura ziftomenib Sale Triggers $135M Kyowa-Kirin Payment
Kura Oncology, Inc. (NASDAQ: KURA) announced completion of the first US commercial sale of KOMZIFTI...
Roche cobas-liat Whooping-Cough Test Secures FDA Clearance
Roche (SWX: ROG, OTCMKTS: RHHBY) announced that its cobas liat system-based point‑of‑care test for whooping...
Henlius HLX37 Bispecific NMPA Approval Targets Advanced Solid Tumors
Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that its self-developed investigational new drug, HLX37 (Recombinant...
Leads-Biolabs LBL047 Bispecific Secures China IND Approval for SLE
Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) announced that the National Medical Products Administration (NMPA)...
Shanghai Bao Pharma IPO HKEX Raises HK$1 Billion for Biotech Pipeline
Shanghai Bao Pharmaceuticals Co., Ltd. (HKG: 2659) successfully listed on the Hong Kong Stock Exchange...
Abbisko ABSK141 KRAS-G12D Inhibitor Secures FDA IND Approval
Abbisko Cayman Limited (HKG: 2256) announced that its Investigational New Drug (IND) application for ABSK141,...